Translational Research Program 2023-2024

The LLS is seeking applications in the following priority areas:

• Understanding of the MCL tumor microenvironment and the properties of lymphoma cells responsible for disease relapse
• Identifying the best treatment combinations based on solid preclinical rationale and data
• Understanding and developing novel immunotherapies for MCL that have the potential to cure cancer
• Identification and validation of novel targets in relapsed disease
• Developing treatment approaches that replace cytotoxics with targeted therapies or immunotherapies that retain efficacy while reducing toxicity
• Understanding the basis of resistance to existing and newly emerging therapies
• Developing novel therapeutics, especially to targets that are unique to MCL and have previously been difficult to drug (e.g., transcription factors)
• Developing additional, accurate animal models of the disease for critical testing of drugs
• Developing predictive biomarkers of disease that can be used for early detection, prediction of treatment response, and to identify patients most likely to respond well to different treatments

Topics of interest include:

• Personalized medicine approach for cancer treatment. 
• Development of novel therapies and/or novel therapeutic strategies .
• Improvements in the safety and efficacy of stem cell transplantation
• Long-term outcomes.
• Cancer Cell/Microenvironment.

Funding: $225,000 per year ($750,000 total) 
Duration: 3 years

Research Authority due date: 12.10.23
LOI (required) due date: 20.10.23
Full proposal due date: 19.1.24